CYTOKINETICS INC — Director's Dealing 2017

Mar 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2017-02-28

Reporting Person: Morgan Bradley Paul (SVP Drug Discovery & Early Dev)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-28	Common Stock	A	15000	$0.0010	Acquired	31180	Direct
2017-02-28	Common Stock	F	5986	$10.6	Disposed	25194	Direct
2017-02-28	Common Stock	A	20000	$0.0010	Acquired	45194	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-28	Incentive Stock Option (right to buy)	$10.6	A	6463	Acquired	2027-02-28	Common Stock (6463)	Direct
2017-02-28	Non-Qualified Stock Option (right to buy)	$10.6	A	13537	Acquired	2027-02-28	Common Stock (13537)	Direct

Footnotes

F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020.

F2: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021.